The latest report on maternal health from The Leapfrog Group shows progress on all three health measures, but there is room for improvement. A record percentage of hospitals achieved Leapfrog’s target for nulliparous, term, singleton, vertex cesarean delivery rates.
In this multicenter study across 12 centers in the United States, a vacuum-induced intrauterine device successfully treated 94% of participants who experienced a postpartum hemorrhage with a median time of three minutes to control of bleeding.
In this retrospective cohort study between May 2007 and April 2016, women undergoing a trial of labor after cesarean (TOLAC) were analyzed to determine if pre-pregnancy or delivery obesity status made an impact on TOLAC success. Overall, maternal body mass index did not have a significant effect on TOLAC success rates.
In this prospective, cohort, pharmacokinetic-pharmacodynamic (PKPD) dose-finding study by Ahmadzia and colleagues, 30 pregnant women (10 women in each study arm) received 5 mg/kg, 10 mg/kg, or 15 mg/kg doses of tranexamic acid for the prevention of postpartum hemorrhage. Advanced PKPD modeling demonstrated that 600 mg of tranexamic acid was the optimal dose to use in the prevention of postpartum hemorrhage.
Physicians sometimes worry that women who have not given birth will have more difficulty with an intrauterine device, experiencing a higher expulsion rate. But the results of a recent study show that the opposite is true.
The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine both recognize cesarean deliveries can save lives, but they advise vaginal deliveries for most pregnancies because the risk is lower than that of cesarean deliveries. The cesarean delivery rate is considered a key indicator of quality and patient safety. Leapfrog reported the average cesarean rate nationwide in 2018 was 26.1%, although the organization set a target of 23.9%.